9.89 USD
↘ 1.31 (11.70%)AT CLOSE (11:59 AM EDT)
REGENXBIO Inc.
RGNXNASDAQ • USD
9.84
↘ 0.05 (0.47%)
POST MARKET (AS OF 07:43 PM EDT)
Post Market
AS OF 07:43 PM EDT
9.84
↘ 0.05 (0.47%)
Market: CLOSED
RGNX is currently priced at $9.87. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Strong Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, RGNX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jul 17, 2026.
Open?$8.99
High?$10.24
Low?$8.42
Prev. Close?$11.20
Volume?7.5M
Avg. Volume?2.5M
VWAP?$9.43
Rel. Volume?3.04x
Bid / Ask
Bid?$8.51 × 100
Ask?$11.33 × 100
Spread?$2.82
Midpoint?$9.92
Valuation & Ratios
Market Cap?579.0M
Shares Out?51.7M
Float?38.7M
Float %?74.9%
P/E Ratio?N/A
P/B Ratio?27.46
EPS?-$5.61
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Themes
Employees
371
Market Cap
579.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2015-09-17
Address
9804 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
Phone: 240-552-8181
ROCKVILLE, MD 20850
Phone: 240-552-8181
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?5
Short Sent.?38
Piotroski F-Score?2/9Weak
Altman Z-Score?-5.71Distress
Confidence?67%Moderate
Short InterestSqueeze Risk
Short % of Float?27.05%Squeeze Risk
Short Interest?10.5M
Days to Cover?3.2
Free Float38.7M
Avg Daily Volume3.3M
Settlement Date2026-06-30
Financial Health
Current Ratio?2.62Strong
Quick Ratio?2.62Strong
Cash Ratio?0.21Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?27.46HIGH▾
Peers100
S&P3
P/S?6.59FAIR▾
Peers100
S&P19
P/FCF?N/A▾
EV/EBITDA?-2.3CHEAP▾
S&P97
EV/Sales?6.42HIGH▾
Peers100
S&P24
Returns & Efficiency
ROE?-1,375.6%WEAK▾
S&P3
ROA?-84.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-236403000
Enterprise Value?$563.8M
Fundamentals ratios updated end of day